Insider trade

CEO exercised or converted 21K ROIV derivative securities

Traded Oct 13, 2025 · Filed Oct 15, 2025

Roivant SciencesROIV

21K
Shares · @ $15.85

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 13, 2025
Reporting period: Not applicable
Filed with the SEC: Oct 15, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-038126

Filed / recorded

Oct 15, 2025, 5:00 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Eric Venker

Relationship

Officer

Officer title

President & Immunovant CEO

Security

Common Shares

Table

Non-derivative (Table I)

Transaction date

Oct 13, 2025

Transaction code

M

Shares / units

20,727

Price per share

$15.85

Acquired / disposed

Acquired (A)

Shares owned after

1,525,686

Ownership form

Direct

Amendment

No

Around the same time

200KShares · @ $3.85

11mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$4.04M of Roivant Sciences

Scheduled in advance11mo ago

200KDerivative units · @ $20.22

11mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record